NEW YORK – Bristol Myers Squibb announced on Tuesday that its acute myeloid leukemia drug enasidenib (Idhifa) combined with best supportive care failed to significantly extend overall survival compared to conventional regimens in relapsed and refractory patients with an IDH2 mutation.